16q24 is frequently deleted in multiple tumors including cancers of nasopharynx, esophagus, breast, prostate and liver. By array comparative genomic hybridization (aCGH), we refined a 16q24 hemizygous deletion in nasopharyngeal carcinoma (NPC) cell lines. Semi-quantitative RT-PCR analysis revealed interferon regulatory factor 8 (IRF8) as the only downregulated gene within this deletion. IRF8 belongs to a family of interferon (IFN) regulatory factors that modulate various important physiologic processes including host defense, cell growth and differentiation and immune regulation. In contrast to the broad expression of IRF8 in normal adult and fetal tissues, transcriptional silencing and promoter methylation of IRF8 were frequently detected in multiple carcinoma (except for hepatocellular) cell lines (100% in NPC, 88% in esophageal and 18-78% in other carcinoma cell lines) and in a large collection of primary carcinomas (78% in NPC, 36-71% in other carcinomas). Methylation of the IRF8 promoter led to the disruption of its response to IFN-c stimulation. Pharmacological and genetic demethylation could restore IRF8 expression, indicating a direct epigenetic mechanism. Ectopic expression of IRF8 in tumor cells lacking its expression strongly inhibited their clonogenicity, confirming its tumor suppressor function. Thus, IRF8 was identified as a functional tumor suppressor, which is frequently silenced by epigenetic mechanism in multiple carcinomas.
Introduction
Carcinogenesis is a multistep process with the accumulation of multiple genetic and epigenetic changes (Jones and Baylin, 2002) . In addition to the contribution of oncogenes, inactivation of tumor suppressor genes (TSGs) is also frequently involved (Jones and Baylin, 2002; Baylin and Ohm, 2006) . Genetic mutations including deletions disrupt TSG functions (Knudson, 2001) , whereas epigenetic silencing also inactivates TSGs through methylation of promoter CpG islands (CGIs), which is a characteristic epigenetic feature of tumor DNA (Jones and Baylin, 2002) .
Nasopharyngeal carcinoma (NPC) is prevalent in Southern China and Southeast Asia (Tao and Chan, 2007) . Although its pathogenesis has been shown to be strongly associated with Epstein-Barr virus, its molecular mechanism is still poorly elucidated (Lo et al., 2004; Tao and Chan, 2007) . Numerous genetic alterations have been detected in NPC cell lines and tumors, including 3p14-22, 11q13.3-24, 13q14.3-22, 14q24.3-32 .1 and 16q21-24 (Chen et al., 1999; Lo et al., 2000; Tao and Chan, 2007) . These regions thus represent the critical TSG loci for NPC. Previous searches for putative TSGs in these regions have identified only few candidates, with tumor-specific promoter methylation, such as BLU and RASSF1A at 3p21 (Lo et al., 2001; Qiu et al., 2004) , CADM1/TSLC1 at 11q23.1 (Lung et al., 2006) ; THY1/CD90 at 11q22.3 (Lung et al., 2005) , CDH1 at 16q22.1 (Chang et al., 2003) , ADAMTS18 and CDH13 at 16q23 (Sun et al., 2007; Jin et al., 2007b) . These limited findings suggest that additional cancerrelated genes are yet to be identified in NPC in the reported regions, or other unidentified loci.
In this study, we have refined a 16q24.1 deletion as one of the critical tumor suppressor loci in NPC cell lines using high-resolution, 1-Mb array comparative genomic hybridization (aCGH) analysis (Ying et al., 2006) . Loss of heterozygosity (LOH) at 16q24 is also frequently present in multiple other solid tumors, such as breast, prostate, hepatocellular and Wilm's tumor (Lo et al., 2000; Paige et al., 2000; Jin et al., 2007b) , suggesting the presence of critical TSG(s) at this locus. Several functional candidate TSGs have been identified at this locus including CDH13 (Toyooka et al., 2001) . Thus, it is needed to search thoroughly for more TSGs at this locus and define their functions in tumors.
Among the genes resided at the 16q24.1 deletion, silencing of interferon regulatory factor 8 (IRF8) was identified in several NPC cell lines. IRF8 is also known as interferon consensus sequence-binding protein (ICSBP), which belongs to the IRF family of transcription factors (Nguyen et al., 1997) . IRF8 has been characterized as a central element of the interferon (IFN)-g-signaling pathway, which modulates immune response and also regulates cell growth and differentiation (Tamura and Ozato, 2002) . IRF8-deficient mice developed a human chronic myelogenous leukemia (CML)-like disease (Holtschke et al., 1996) . In patients with CML and acute myelogenous leukemia, IRF8 expression was dramatically decreased, suggesting that IRF8 could be a candidate TSG (Schmidt et al., 1998) .
Here, we report the frequent epigenetic inactivation of IRF8 in NPC, as well as other common carcinomas, such as esophageal, breast, cervical, lung and colorectal carcinomas. Methylation of the IRF8 promoter abolishes its response to IFN-g. Moreover, ectopic expression of IRF8 in silenced tumor cells strongly inhibited their clonogenicity, indicating that IRF8 is a functional TSG.
Results
Identification of IRF8 as a downregulated gene in NPC Genetically altered regions pinpoint the loci of TSGs. We attempted to identify novel TSGs through an integrative cancer epigenetic approach by coupling 1-Mb aCGH with expression analysis. A hemizygous deletion represented by a bacterial artificial chromosome (BAC) clone bA478M13 (tumor/normal log2 signal ratio À0.45) was detected in 1 of 6 NPC cell lines. Bioinformatics search using the Ensembl Genome Browser (www.ensembl.org/index.html) mapped this clone to locus 16q24.1, spanning B160-kb, with three genes, COX4NB, COX4I1 and IRF8 residing at this locus ( Figure 1a ). Semi-quantitative RT-PCR analysis revealed IRF8 silencing in 5 of 6 NPC cell lines with weak expression in C666-1, but not for the other two genes COX4NB and COX4I1, suggesting that IRF8 is the candidate TSG located at the 16q24.1 deletion (Figure 1b) .
Frequent downregulation of IRF8 in multiple carcinomas
We further determined IRF8 expression in a panel of normal adult and fetal tissues and multiple cell lines by semi-quantitative RT-PCR. IRF8 expression was detected in all normal tissues including nasopharynx and esophagus (Figure 1d ), as well as immortalized normal nasopharyngeal (NP69) and esophageal epithelial (NE1 and NE3) cell lines (Figure 2a ). In contrast, IRF8 was frequently downregulated or silenced in carcinoma cell lines of nasopharyngeal, esophageal, breast, lung, cervical and colorectal carcinomas (Figure 2a ), but less frequently in gastric and seldom in hepatocellular carcinoma cell lines (Supplementary Figure) . Meanwhile, expression of the IRF8 protein was confirmed by western blot in normal esophageal epithelial tissues and normal lymphoid cell line LCL-CCL256.1 (Figure 2b ). However, IRF8 was absent in HONE1 and HCT116 cell lines that are completely methylated and silenced for this gene.
Methylation of the IRF8 promoter correlates with its transcriptional silencing We then examined the possible genetic/epigenetic mechanisms of IRF8 downregulation. As predicted by online CpG Island Searcher (http://cpgislands.usc.edu/), there is a CGI spanning the transcription start site of IRF8 (Figure 1c ). Methylation-specific PCR (MSP) was thus performed to study the methylation status of this CGI. Results showed that IRF8 was frequently methylated in cell lines with downregulation (6 of 6 nasopharyngeal, 14 of 16 esophageal, 7 of 9 breast, 3 of 4 colorectal, 5 of 7 lung, 4 of 6 cervical and 3 of 17 gastric carcinoma cell lines) (Figure 2a Table 1 ), whereas no methylation was detected in the immortalized epithelial cell lines (NP69, NE1 and NE3), indicating that methylation is tumor specific (Figure 2a ). The presence of either unmethylated or methylated promoter alleles in virtually all cell lines including silenced ones indicates the absence of homozygous deletion of IRF8 promoter in these cell lines, except for LoVo with weak bands indicating possible hemizygous deletion.
To confirm the MSP results in higher resolution, bisulfite genomic sequencing (BGS) was performed to examine the methylation status of 43 individual CpG sites (À596 to À175, relative to the transcription start site) within the IRF8 promoter CGI. The BGS results were consistent with those of MSP in which dense methylation was only observed in methylated cell lines, but not in unmethylated non-tumor cell line NP69 (Figure 2c) . Thus, the results revealed a strong correlation between IRF8 transcriptional silencing and its promoter methylation.
IRF8 promoter methylation disrupts its response to IFN-g We further examine whether the IRF8 response to IFN-g stimulation would be affected by the promoter methylation of this gene. IFN-g treatment of normal and tumor cell lines with an unmethylated (HEK 293 and HCT116-DKO) or weakly methylated (HepG2) promoter led to the induction of IRF8 expression. However, this response was abolished in cell lines with predominantly methylated promoter (HONE1, KYSE520 and HCT116) (Figure 3 ). These results suggest that epigenetic silencing of IRF8 disrupted its response to IFN-g.
Pharmacological and genetic demethylation reactivates IRF8 expression
To examine whether promoter methylation directly mediates the silencing of IRF8, cell lines (BT549, MB231, T47D, CNE1, HK1, HONE1, KYSE510 and KYSE520) were treated with demethylation agent 5-aza-2-deoxycytidine (Aza), with or without histone deacetylase inhibitor trichostatin A (TSA). After the treatment, IRF8 expression levels were dramatically increased in all cell lines examined (Figure 4a) decrease in methylated alleles and increase in unmethylated alleles of the IRF8 promoter (Figure 4b ). Combined Aza and TSA treatment led to higher IRF8 expression levels (Figure 4a ).
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We also found that the IRF8 could be activated in the colorectal carcinoma cell lines HCT116 by genetic demethylation through double knockout of DNA methyltransferases (DNMTs) 1 and 3B (DKO cell line) (Figure 4a) . Concomitantly, the IRF8 promoter was dramatically demethylated in DKO cells as compared to HCT116 cells (Figure 4b ). Further high-resolution methylation analysis by BGS confirmed the demethylation of IRF8 (Figure 4c) , suggesting that the maintenance of IRF8 methylation is mediated by DNMT1 and 3B, such as other bona fide TSGs we and others previously reported (Ying et al., 2006; Jin et al., 2007a, b) . Taken together, these results demonstrate that promoter methylation directly contributes to the downregulation of IRF8 in multiple carcinomas.
Frequent IRF8 methylation in multiple primary carcinomas
We next investigated IRF8 methylation in a large collection of primary carcinomas (n ¼ 113), including NPC, esophageal, breast and cervical carcinomas, together with normal epithelial tissues as controls. IRF8 methylation was detected in 35 of 46 (76%) endemic NPC tumors from Asian Chinese and all three nude mice-passaged undifferentiated NPC tumors from North African (C15, C17 and C18) (Figure 5b ) (Busson et al., 1988) , with no methylation detected in any normal nasopharyngeal tissue (Figure 5a ). IRF8 methylation was also found in 25 of 43 (58%) esophageal carcinomas, whereas only two of the 43 paired surgical marginal esophageal tissues showed methylation (Figure 5b ), and none of the 10 normal esophageal tissues from healthy individuals had methylation (Figure 5a ). Furthermore, IRF8 methylation was detected in 5 of 14 (36%) primary breast carcinomas, and 5 of 7 (71%) of primary cervical carcinomas ( Figure 5b and Figures 6a and c) . Thus, IRF8 indeed possesses growth inhibitory activities in tumor cells and is a functional tumor suppressor.
Discussion
In this report, we used an integrative epigenetic approach combining aCGH with RT-PCR analysis to screen for downregulated genes in NPC, and identified an IFN regulatory factor, IRF8, as a candidate TSG. We further showed that IRF8 is frequently silenced by promoter methylation in a tumor-specific manner, not only in NPC, but also in other common cancers, such as esophageal, breast, cervical, lung and colorectal carcinomas. The response of IRF8 to IFN-g treatment was abolished in those cell lines with methylated promoter. In addition, we showed that ectopic expression of IRF8 in silenced carcinoma cell lines dramatically inhibits their clonogenicity. Thus, IRF8 behaves as a functional TSG in multiple cancers, and might be important in their pathogenesis. Epigenetic gene silencing is associated with the onset and progression of various cancers (Jones and Baylin, 2002) . Multiple studies tried to identify TSGs silenced by DNA methylation. Compared to other common carcinomas, such as breast, colon and lung cancers, NPC is not well studied and its molecular pathogenesis poorly known. Thus, we used an integrated genomic and epigenetic approach to identify NPC-related TSGs, and successfully refined a hemizygous deletion at 16q24.1 in NPC cell lines, We further identified IRF8 as the only downregulated gene within this deleted region. The downregulation of IRF8 is well correlated with its inactivation of IRF8 could be a common and important step during NPC tumorigenesis. IRF8 is a transcription factor of the IRF gene family, which includes IRF1-8 and IRF9/ISGF3g (Nguyen et al., 1997) . Among them, IRF1 and IRF5 have been shown to exert tumor suppressor activities in multiple carcinomas and induce tumor cell apoptosis (Bouker et al., 2005; Hu et al., 2005; Watson et al., 2006) . The expression of IRF8 is regulated by IFN-g, a proinflammatory cytokine (Yang et al., 2007b) . IFN-g exerts its growth inhibitory effect on tumor cells through IFNsignaling pathway (STATs) and the induction of IRF1 and 8 in mouse model (Egwuagu et al., 2006) . We found that IRF8 promoter methylation abolishes its response to IFN-g in tumor cells. When inspecting the IRF8 promoter, an IFN-g activation site (GAS) with a single CpG site is present at À145 to À131 (GATTTCTCG GAAAGC). It is very likely that methylation of this CpG site would affect the binding of transcription factors and the IRF8 response to IFN-g. IRF8 promoter methylation could then enable tumor cells to escape IFN-g-mediated apoptosis, thus involved in carcinogenesis.
As a transcription factor, IRF8 probably functions as a tumor suppressor through inducing the transcription of TSGs and apoptotic genes and repressing the expression of oncogenic genes. For examples, IRF8 forms a complex with PU.1 to activate the transcription of p15 INK4B /CDKN2B, a bona fide TSG, in murine myeloid cells in response to IFNaˆtreatment (Schmidt et al., 2004) . IRF8 also induces the expression of multiple TSGs such as NF1 (Zhu et al., 2004; Tamura et al., 2005) and apoptotic genes such as FAS (Yang et al., 2007a, b) , and represses the expression of the oncogenic BCR/ABL and antiapoptotic BCL2 (Tamura et al., 2003; Burchert et al., 2004) .
The expression and function of IRF8 has long been thought to be limited to hematopoietic cells (Tamura and Ozato 2002; Kanno et al., 2005) . The tumor suppressor function of IRF8 in both chronic and acute myelogenous leukemia has been further verified in IRF8 À/À mice, which developed a CML-like syndrome (Holtschke et al., 1996) . However, IRF8 is much less characterized in epithelial tumors. Very recently, Yang et al. (2007b) reported that IRF8 is repressed by methylation in a single colon cell line (SW620), which is related to apoptotic resistance and tumor metastasis. Consistently, we detected frequent IFR8 downregulation by promoter methylation in other colon cell lines, HCT116, HT-29 and LoVo. Furthermore, genetic demethylation (through double knockout of DNMT1 and 3B in HCT116) restored IRF8 expression, providing direct evidence that IRF8 silencing in HCT116 is due to its aberrant promoter methylation governed by both DNMT1 and 3B. We also analysed IRF8 expression in multiple carcinomas, and demonstrated that IRF8 acts as a tumor suppressor in NPC, esophageal and colorectal tumor cells. Our study thus greatly extends the current knowledge of IRF8 functions in normal and tumorous nonhematopoietic cells.
LOH of 16q24 was frequently detected in a variety of cancers (Lo et al., 2000; Paige et al., 2000; Jin et al., 2007b) , suggesting that IRF8 may be a critical tumor suppressor in multiple carcinomas. Our studies revealed that the epigenetic inactivation of IRF8 is common in other multiple cancers, such as esophageal, breast, cervical and lung carcinomas. We confirmed that IRF8 functions as a general tumor suppressor by colony formation assay in NPC, esophageal and colon carcinoma cell lines. We also noticed that normal IRF8 expression is maintained in all the immortalized epithelial cell lines, comparable to normal tissues, indicating that IRF8 methylation is not an early event during carcinogenesis and not methylated during immortalization.
In summary, we found that IRF8 is frequently inactivated by promoter methylation in multiple tumors including NPC, esophageal, cervical, breast, lung and colorectal carcinomas, which disrupts its response to IFN-g-induced activation. We further demonstrated that IRF8 could act as a functional TSG in multiple carcinoma cells. Considering the high incidence of epigenetic silencing of IRF8 in NPC, cervical and esophageal carcinomas, it would thus be worthy exploring further the possible use of IRF8 methylation as an epigenetic biomarker for the molecular diagnosis and prognosis predictions of these tumors.
Materials and methods
Cell lines, tumor and normal tissue samples A series of carcinoma cell lines were studied, including nasopharyngeal, esophageal, breast, lung, cervical and colorectal cancers (Ying et al., 2006; Jin et al., 2007a, b) . Immortalized normal epithelial cell lines NP69, NE1 and NE3 (Tsao et al., 2002) , HEK 293 and the lymphoblastoid cell line (LCL) CCL256.1 (Tao et al., 2002) were used as controls. Colon HCT116 cell lines with double knockout of DNMTs: HCT116 DNMT1
À/À DNMT3B À/À (DKO) cells (gifts of Bert Vogelstein, Johns Hopkins) were used (Rhee et al., 2002) .
Human normal adult and fetal tissue RNA samples were purchased commercially (Stratagene, La Jolla, CA, USA or Millipore Chemicon, Billerica, MA, USA) (Ying et al., 2006) . Samples of normal nasopharyngeal tissues and normal esophageal epithelial tissues were described previously (Srivastava et al., 2000; Wong et al., 2006) . DNA samples from various primary carcinoma samples, 46 Asian Chinese NPC, three nude mice-passaged NPC tumors derived from North Africans, 43 esophageal squamous cell carcinomas (T) and their corresponding surgical marginal normal tissues (N), seven cervical carcinomas and 14 breast carcinomas were described previously (Steenbergen et al., 2004) .
Cell treatments
Cell lines were treated with Aza (Sigma, St Louis, MO, USA) and TSA as described previously (Ying et al., 2006) . For the treatment of IFN-g, cells were seeded in six-well plate the day before treatment, medium was changed and recombinant human IFN-g (Millipore) was added to the culture to a final concentration of 250 U/ml. Cells were harvested 24-h posttreatment for analysis (Yang et al., 2007b) .
Array-CGH
Whole-genome arrays (1 Mb resolution) with 3040 BAC/PAC clones were used (Wellcome Trust Sanger Institute, Cambridge, UK), (www.ensembl.org/Homo_sapiens/index.html). aCGH was performed and analysed as described previously (Ying et al., 2006) .
Semi-quantitative RT-PCR analysis
Reverse transcription-PCR (RT-PCR) was performed for 36 cycles with hot-start, using AmpliTaq Gold DNA Polymerase (Applied Biosystems, Foster City, CA, USA) as previously reported.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a control (Tao et al., 2002) . RT-PCR primers were designed to span introns to prevent amplification of genomic DNA. Primer sequences are provided in Supplementary Table 1 .
Western blotting analysis
Western blotting analysis was performed as previously described (Ying et al., 2008) . Antibody against IRF8 (a´-ICSBP/IRF8, C-19) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and antibody against tublin was purchased from Neomarkers (Fremont, CA, USA).
Bisulfite treatment and promoter methylation analysis Bisulfite modification of DNA, MSP and BGS were carried out as previously described (Tao et al., 2002; Ying et al., 2006) . Both MSP and BGS were performed for 40 cycles using AmpliTaq Gold DNA Polymerase with hot-start. MSP primers were tested for not amplifying any unbisulfited DNA. For BGS, the PCR products were cloned into pCR4-TOPO (Invitrogen, Carlsbad, CA, USA). Four to six colonies were randomly chosen and sequenced. Primer sequences are shown in Supplementary Table 1.
Colony formation assay
Mammalian expression vector pcDNA3.1( þ )-IRF8 encoding the full-length open reading frame of human IRF8 gene was constructed and used (Hashmueli et al., 2003) . For colony formation assay using monolayer culture, cells (2 Â 10 5 per well) were plated in a 12-well plate and transfected with expression plasmids pcDNA3.1( þ )-IRF8 or the empty vector pcDNA3.1( þ ) (0.5 mg each), using Fugene6.0 (Roche, Basel, Switzerland). Cells were collected and plated in a six-well plate 48 h post-transfection, and selected for 10-14 days with G418 (0.4 mg/ml). Surviving colonies (X50 cells per colony) were counted after staining with Gentian Violet (ICM Pharma, Singapore). Total RNA from the transfected cells was extracted, treated with DNase I and analysed by RT-PCR to confirm the expression of IRF8. All the experiments were performed in triplicate wells for three times. Data were presented as relative colony formation ability ± s.d. Statistical analysis was carried out by Student's t-test, a Po0.05 was considered as statistically significant difference.
